NASDAQ:NERVMinerva Neurosciences Stock Price, Forecast & News

Minerva Neurosciences' stock was trading at $6.36 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, NERV shares have increased by 124.5% and is now trading at $14.28. View which stocks have been most impacted by Coronavirus.

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Minerva Neurosciences in the last year. There are currently 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Minerva Neurosciences.

Minerva Neurosciences is scheduled to release its next quarterly earnings announcement on Monday, August 3rd 2020. View our earnings forecast for Minerva Neurosciences.

Minerva Neurosciences Inc (NASDAQ:NERV) released its earnings results on Monday, May, 4th. The biopharmaceutical company reported ($0.31) EPS for the quarter, beating the consensus estimate of ($0.36) by $0.05. View Minerva Neurosciences' earnings history.

5 equities research analysts have issued 12-month target prices for Minerva Neurosciences' shares. Their forecasts range from $17.00 to $26.00. On average, they expect Minerva Neurosciences' share price to reach $20.80 in the next twelve months. This suggests a possible upside of 45.7% from the stock's current price. View analysts' price targets for Minerva Neurosciences.

Press coverage about NERV stock has been trending extremely negative recently, InfoTrie Sentiment Analysis reports. The research firm identifies negative and positive press coverage by reviewing more than six thousand news and blog sources in real-time. The firm ranks coverage of public companies on a scale of negative five to five, with scores nearest to five being the most favorable. Minerva Neurosciences earned a media sentiment score of -4.5 on InfoTrie's scale. They also gave media coverage about the biopharmaceutical company a news buzz of 10.0 out of 10, meaning that recent press coverage is extremely likely to have an effect on the company's share price in the next several days. View the latest news aboutMinerva Neurosciences.

Minerva Neurosciences saw a decline in short interest in May. As of May 15th, there was short interest totaling 2,820,000 shares, a decline of 5.4% from the April 30th total of 2,980,000 shares. Based on an average daily volume of 392,500 shares, the days-to-cover ratio is presently 7.2 days. Currently, 9.0% of the shares of the stock are short sold. View Minerva Neurosciences' Current Options Chain.

Some companies that are related to Minerva Neurosciences include Principia Biopharma (PRNB), Prestige Consumer Healthcare (PBH), Turning Point Therapeutics (TPTX), SAGE Therapeutics (SAGE), Madrigal Pharmaceuticals (MDGL), Ironwood Pharmaceuticals (IRWD), Pacira Biosciences (PCRX), Epizyme (EPZM), Aurinia Pharmaceuticals (AUPH), Corcept Therapeutics (CORT), Xencor (XNCR), IGM Biosciences (IGMS), Ligand Pharmaceuticals (LGND), Eidos Therapeutics (EIDX) and Theravance Biopharma (TBPH). View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Minerva Neurosciences investors own include PTC Therapeutics (PTCT), Inovio Pharmaceuticals (INO), Immunomedics (IMMU), Advanced Micro Devices (AMD), Gilead Sciences (GILD), ImmunoGen (IMGN), VBI Vaccines (VBIV), Exelixis (EXEL), TG Therapeutics (TGTX) and Cara Therapeutics (CARA).

Minerva Neurosciences trades on the NASDAQ under the ticker symbol "NERV."

Minerva Neurosciences' stock is owned by a variety of institutional and retail investors. Top institutional investors include BlackRock Inc. (5.33%), State Street Corp (1.31%), Geode Capital Management LLC (1.25%), Nuveen Asset Management LLC (1.03%), Acadian Asset Management LLC (0.48%) and Sphera Funds Management LTD. (0.43%). Company insiders that own Minerva Neurosciences stock include David Kupfer, Frederick W Ahlholm, Geoff Race, Joseph H Reilly, Remy Luthringer, Richard E Russell, Venture Associates L Index III and William F Doyle. View institutional ownership trends for Minerva Neurosciences.

NERV stock was sold by a variety of institutional investors in the last quarter, including Sphera Funds Management LTD., JPMorgan Chase & Co., Squarepoint Ops LLC, State Street Corp, GSA Capital Partners LLP, Connor Clark & Lunn Investment Management Ltd., Morgan Stanley, and BlackRock Inc.. Company insiders that have sold Minerva Neurosciences company stock in the last year include Frederick W Ahlholm, Geoff Race, Joseph H Reilly, Remy Luthringer, and Venture Associates L Index III. View insider buying and selling activity for Minerva Neurosciences.

NERV stock was purchased by a variety of institutional investors in the last quarter, including Nuveen Asset Management LLC, Deutsche Bank AG, Russell Investments Group Ltd., Acadian Asset Management LLC, AQR Capital Management LLC, Geode Capital Management LLC, Two Sigma Advisers LP, and Trexquant Investment LP. Company insiders that have bought Minerva Neurosciences stock in the last two years include David Kupfer, and William F Doyle. View insider buying and selling activity for Minerva Neurosciences.

Shares of NERV can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of NERV stock can currently be purchased for approximately $14.28.

Minerva Neurosciences has a market capitalization of $560.06 million. The biopharmaceutical company earns $-72,180,000.00 in net income (profit) each year or ($1.85) on an earnings per share basis. Minerva Neurosciences employs 13 workers across the globe.

The official website for Minerva Neurosciences is www.minervaneurosciences.com.

Minerva Neurosciences' mailing address is 1601 TRAPELO ROAD SUITE 286, WALTHAM MA, 02451. The biopharmaceutical company can be reached via phone at 617-600-7373 or via email at [email protected]